MYNZ (Mainz Biomed) רווח נקי למניה (EPS TTM)

Mainz Biomed N.V. (MYNZ) generates revenue through the implementation of the ColoAlert non-invasive analysis for the early detection of colorectal cancer. This annual net income per share chart reflects a trend where the current value stands at 0.00. Business efficiency is increasing through outsourced IT support and contract manufacturing. The company is scaling its presence in North America and Europe, advancing the field of preventive medicine.
פילוחי מדדים ואנליטיקה של חברת Mainz Biomed (MYNZ)

Earnings per share (EPS TTM) measures the portion of annual net income allocated to each ordinary share. Growth in this metric confirms capital generation efficiency and the business's resilience to inflation. By analyzing earnings per share over the last 12 months, an investor assesses the real cost of asset ownership. For Mainz Biomed N.V. (MYNZ), this trend is critical due to regulatory risks in the EU and US. Geopolitical barriers directly impact the export of diagnostics, which is reflected in the bottom line.